Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Silvia Delgado(Behavioral Pharma (United States)), Kottil Rammohan(Martin College), Simon Faissner(St. Josef-Hospital), Ralf A. Linker(St. Josef-Hospital)
Cited by 49
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
|Brain|2011|1.2k